ID   B250
AC   CVCL_L054
DR   Wikidata; Q54752580
RX   PubMed=1817649;
RX   PubMed=9680106;
CC   Population: Japanese.
CC   Doubling time: 30-36 hours (PubMed=1817649).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1836 ! NALM-20
OI   CVCL_1837 ! NALM-21
OI   CVCL_5662 ! NALM-22
OI   CVCL_5663 ! NALM-23
SX   Male
AG   62Y
CA   Transformed cell line
DT   Created: 06-05-13; Last updated: 29-06-23; Version: 10
//
RX   PubMed=1817649;
RA   Matsuo Y., Ariyasu T., Ohmoto E., Kimura I., Minowada J.;
RT   "Bi-phenotypic t(9;22)-positive leukemia cell lines from a patient
RT   with acute leukemia: NALM-20, established at the onset; and NALM-21,
RT   NALM-22 and NALM-23, established after relapse.";
RL   Hum. Cell 4:335-338(1991).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//